1. Medtech Insight

Tough Investigator And Universal-Coverage Proponent Rep. John Dingell Dead At 92

 
• By Sue Darcey

Former House Energy and Commerce Committee Chairman John Dingell Jr., D-Mich., who was a fierce investigator of federal agencies including US FDA and sponsor of the Affordable Care Act and other legislation impacting the device industry, died at age 92 Thursday at his home in Dearborn, Mich.

John Dingell
Former Rep. John Dingell, D-Mich., led multiple investigations in US FDA regulatory activities during his decades on Capitol Hill. • Source: LBJ Library

Former Congressman John Dingell Jr., D-Mich., who died Feb. 7, will be remembered by the medtech industry for his strong and forceful oversight of the US FDA device and drug centers, introduction of the Affordable Care Act, and sponsorship of medtech legislation.

The longest-serving US member of Congress in history, who is probably best known for his investigations into government health-care activities and his consistent push for universal health insurance, had been...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.